A Randomized Phase 3 Study of Tasisulam Administered as an Intravenous Infusion on Day 1 of a 28-Day Cycle vs. Paclitaxel as Second-Line Treatment in Patients With Metastatic Melanoma.

Trial Profile

A Randomized Phase 3 Study of Tasisulam Administered as an Intravenous Infusion on Day 1 of a 28-Day Cycle vs. Paclitaxel as Second-Line Treatment in Patients With Metastatic Melanoma.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 26 Mar 2014

At a glance

  • Drugs Paclitaxel (Primary) ; Tasisulam (Primary)
  • Indications Malignant melanoma
  • Focus Registrational; Therapeutic Use
  • Acronyms SUMMIT-1
  • Most Recent Events

    • 26 Mar 2014 Results published in the Cancer.
    • 16 Mar 2011 Status changed from suspended to discontinued as reported by ClinicalTrials.gov.
    • 13 Dec 2010 Status changed from recruiting to suspended.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top